Skip to main content

RheumNow Week in Review - 3 June 2016

Jun 03, 2016 2:40 pm

This week's highlights from include:

  1. In a study of knee OA patients they examined the frequency of venous thrombotic events (VTE) (n=4020) and compared with controls having VTE(1:5). NSAID use (diclofenac, meloxicam, ibuprofen, coxibs; but not naproxen) was associated with a ~40% increase VTE risk.
  2. Myositis experts consensus says that after steroids, azathioprine, methotrexate and mycophenolate are most commonly chosen agents to manage myositis.
  3. FDA rules to lower salt content by manufacturers & restaurants – recommending a decrease in daily salt  intake from 3.4 to 2.3 g/day. 
  4. 1487 patients with low back pain were reviewed for their medication use. Low rates of med use found: only 18.7% taking meds for back pain; anxiolytics 14%; NSAIDs 12%; analgesic 7%; muscle relaxants 3%; opioids 1.6%.
  5. Recurrent acute anterior uveitis responds to golimumab 50 mg qmo; 12/15 eyes from B27+ AS patients improve, going into remission
  6. Samsung Bioepis has a new biosimilar “Flixabi” (a Remicade biosimilar) approved for all 6 indications in 28 EU states & Norway, Iceland.
  7. Morning Stiffness Madness - Dr. Cush debunks the importance of morning stiffness as an inflammatory indicator. 
  8. Patient Reluctance to Take Bisphosphonates
  9. Lower GI Perforation Risk Noted for Tofacitinib and Tocilizumab
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.